Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.663586 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.663586 33859652!8043070!33859652     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33859652&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 663586 Nephropedia Template TP {{tp|p=33859652|t=2021. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities |pdf=|usr=}}{{33859652}} gab.com Text Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33859652 #FOAvip As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world. As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19. Several vaccines, including mRNA, vector-based vaccines, and inactivated vaccines, have been approved for emergency use in various countries. However, the slow roll-out of vaccines and insufficient global supply remains a challenge to turn the tide of the pandemic. Moreover, vaccines are important tools for preventing the disease but therapeutic tools to treat patients are also needed. As such, since the beginning of the pandemic, repurposed FDA-approved drugs have been sought as potential therapeutic options for COVID-19 due to their known safety profiles and potential anti-viral effects. One of these drugs is ivermectin (IVM), an antiparasitic drug created in the 1970s. IVM later exerted antiviral activity against various viruses including SARS-CoV-2. In this review, we delineate the story of how this antiparasitic drug was eventually identified as a potential treatment option for COVID-19. We review SARS-CoV-2 lifecycle, the role of the nucleocapsid protein, the turning points in past research that provided initial 'hints' for IVM's antiviral activity and its molecular mechanism of action- and finally, we culminate with the current clinical findings. Twit Text FOAVip Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33859652 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33859652 #FOAvip English Wikipedia <ref>{{Cite pmid|33859652}}</ref> Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities #MMPMID33859652 Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH Front Immunol 2021[]; 12 (ä): 663586 PMID33859652show ga As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world. As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19. Several vaccines, including mRNA, vector-based vaccines, and inactivated vaccines, have been approved for emergency use in various countries. However, the slow roll-out of vaccines and insufficient global supply remains a challenge to turn the tide of the pandemic. Moreover, vaccines are important tools for preventing the disease but therapeutic tools to treat patients are also needed. As such, since the beginning of the pandemic, repurposed FDA-approved drugs have been sought as potential therapeutic options for COVID-19 due to their known safety profiles and potential anti-viral effects. One of these drugs is ivermectin (IVM), an antiparasitic drug created in the 1970s. IVM later exerted antiviral activity against various viruses including SARS-CoV-2. In this review, we delineate the story of how this antiparasitic drug was eventually identified as a potential treatment option for COVID-19. We review SARS-CoV-2 lifecycle, the role of the nucleocapsid protein, the turning points in past research that provided initial 'hints' for IVM's antiviral activity and its molecular mechanism of action- and finally, we culminate with the current clinical findings. |*COVID-19 Drug Treatment[MESH] |Active Transport, Cell Nucleus/*drug effects[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |Cell Line[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Nucleocapsid Proteins/antagonists & inhibitors/metabolism[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Ivermectin/*therapeutic use[MESH] |Phosphoproteins/antagonists & inhibitors/metabolism[MESH] |Protein Transport/drug effects[MESH] |SARS-CoV-2/*drug effects/growth & development[MESH] |Vero Cells[MESH] |Virus Replication/drug effects[MESH] |alpha Karyopherins/antagonists & inhibitors[MESH]Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic(epmc).pdf DeepDyve Pubget Overpricing